Variables | Adjusted HR (95% CI) | p Value |
Oseltamivir treatment | 0.27 (0.13 to 0.55) | <0.001 |
Age >70 years | 2.94 (0.85 to 10.18) | 0.088 |
Male sex | 3.92 (1.80 to 8.57) | 0.001 |
Major co-morbidity | 2.28 (1.02,5.09) | 0.045 |
Ventilatory support | 8.29 (3.97 to 17.29) | <0.001 |
Nursing home resident | 7.62 (3.51 to 16.54) | <0.001 |
Refer to tables 1 and 2 for explanation of variables compared. The outcome analysed was death that occurred within 21 days of hospitalisation. Potential confounders including ‘time from symptom onset to presentation’, ‘chronic lung diseases’ and ‘negative antigen test result’ were adjusted for in this model. Being managed in either hospital site was not found to affect outcomes in the model. There was also no significant difference in mortality found between influenza A and B subtypes.